Chronic lung infection with mucoid Pseudomonas aeruginosa is the major pathologic feature of cystic fibrosis.
Chronic respiratory tract infections with strains of Pseudomonas aeruginosa elaborating large quantities of mucoid exopolysaccharide (MEP; also called alginate) constitute the major pathologic factor in chronic lung disease and death in patients with cystic fibrosis (CF) (7, 8, 11) . Although little is known about the mechanisms that enable P. aeruginosa to initiate infection in CF patients, this ability is likely related to disruptions in the physiology and chemistry of the respiratory mucus of CF patients and the expression of adhesins for epithelial cells and mucins by P. aeruginosa (12, 26, 28, 29, 32) . The strains initiating infection are phenotypically distinct from those that emerge to cause chronic infection (19) . Specifically, initially infecting strains tend to elaborate a smooth lipopolysaccharide (LPS) containing long 0 side chains, and they are resistant to the bactericidal effects of serum (19) . In contrast, chronically colonizing strains undergo phase variations that result in the emergence of LPS-rough, serum-sensitive strains producing copious amounts of MEP. An intense immune response to multiple bacterial antigens, including MEP, ensues (5, 15, 16, 21, 25, 33) , but the antibodies produced during infection are clearly ineffective at eliminating the bacteria.
Previous work has suggested that the inability of CF patients to effectively deal with chronic P. aeruginosa infection is associated with the production of antibodies to MEP that fail to mediate opsonic killing of the bacteria in vitro (2, 22) . A few older CF patients (>12 years) not chronically colonized have been described; these individuals possess MEP-specific serum antibodies that do mediate in vitro opsonic killing. Protection t Present address: The Miriam Hospital, Providence, RI.
of rodents against chronic endobronchial infections with mucoid P. aeruginosa was found to be mediated by opsonic-but not nonopsonic-MEP-specific antibodies (23) . Although CF patients do develop high titers of opsonic antibodies to P. aeruginosa during infection, these antibodies are directed not at MEP but at bacterial surface antigens located below the MEP capsular layer (22) . The non-MEP-specific opsonins deposit C3b and C3bi below the MEP layer (20) , where they may be unable to interact with complement receptors on polymorphonuclear leukocytes, particularly in vivo, where the bacteria have been shown by numerous studies to grow in MEP-encased microcolonies (4, 14, 35) . Indeed, recent studies support this idea: antibodies in sera from chronically colonized CF patients have a markedly reduced ability to mediate opsonic killing of mucoid P. aeruginosa growing as a biofilm in vitro (18) .
The infrequency with which MEP-specific opsonic antibody is detected in sera from chronically infected CF patients appears not to be related to the underlying,genetic condition but rather to be characteristic of humans in general. We and others have documented moderate titers of naturally occurring antibodies to MEP among persons without CF (5, 21, 36) , but these antibodies are nearly universally nonopsonic (22, 23) . In mice, preexisting nonopsonic antibody to MEP prevents the production of MEP-specific opsonic antibodies when an appropriate dose of MEP antigen is subsequently administered (9) . This effect has been associated with the ability of the MEP antigen and nonopsonic antibodies to form an immune complex; this complex binds to Fc receptors on the surfaces of T cells that can mediate cytotoxic killing of hybridoma cells secreting MEP-specific opsonic antibody (24) . Similar immune complexes in the sera of colonized CF patients sensitized activated human peripheral-blood T cells for cytotoxic activity against the hybridoma cells (24).
From these results, we hypothesize that the progression of chronic lung infections with mucoid P. aeruginosa in CF patients is due to a lack of production of MEP-specific opsonins. To Vaccine antigens. Two lots of MEP vaccine (human lots 1 and 2) were prepared from mucoid P. aeruginosa strain 2192. Human lot 1 was the same as the MEP lot 1 antigen described previously (9); human lot 2 was comparable to but distinct from the MEP lot 2 antigen described previously (9) . Human lot 2 was prepared as described for MEP lot 2 (9). Human lots 1 and 2 differed with regard to the medium used to grow the bacteria for vaccine production and with regard to molecular size (9) but were otherwise comparable.
Vaccines for human use were commercially bottled (Bellmore Laboratories, Hampstead, Md.) and commercially evaluated for safety and pyrogenicity in animals and for endotoxin content (South Mountain Laboratories, Orange, N.J.) to comply with the requirements of the U.S. Food and Drug Administration. Before being administered to humans, all vaccines were evaluated for immunogenicity in mice, as described elsewhere (9 24 h, and 48 h after vaccination. The local and systemic responses described in these interviews were graded on a subjective scale of 0 to 3, with the respective scores representing absent, mild, moderate, and severe reactions. In addition, vaccinates were instructed to take their temperatures 2 to 3 times a day during this period and were provided with logs in which to record any reactions thought to be associated with immunization.
Immunologic analysis. The opsonophagocytic assay and the inhibition of opsonophagocytosis were performed as described previously (2, 9, 22 Derivation of antibodies from transformed peripheral-blood leukocytes. For the separation of human peripheral-blood T and B cells, rosetting of 2-aminoethyl-isothiouronium bromide-treated sheep erythrocytes with the T cells was followed by Ficoll-Hypaque density-gradient separation (13) . The Bcell-enriched band was recovered, washed three times with RPMI tissue culture medium, and then infected with a supernatant of the B95-8 marmoset cell line (ATCC CRL 1612) containing Epstein-Barr virus (EBV) (37) . Cultures were grown in complete RPMI 1640 medium supplemented with 10% fetal calf serum, streptomycin (1 mg/ml), and penicillin (1 mg/ml) at 37°C in 5% CO2. Supernatants were harvested after 2 to 3 weeks of culture. Ammonium sulfate was added to 50% of saturation to precipitate antibodies, which were then recovered by centrifugation, redissolved in water, and dialyzed against phosphate-buffered saline. The final antibody solutions were adjusted to a constant concentration factor based upon the initial amount of cell supernatant used in preparing the antibodies. When supernatants from EBV-transformed cells were tested in the opsonophagocytic assay, controls containing only the supernatant and bacteria were run to ensure that no Statistical analyses. The significance of differences in ELISA and opsonic titers between preimmunization and postimmunization serum samples and that of differences in titer among samples tested in the opsonophagocytic inhibition assays were determined by using a Wilcoxon signed-rank test; that of differences in titer among individuals immunized with different doses of the vaccine was determined by the KruskalWallis test; and that of differences in titer between groups receiving different vaccine doses was determined by the Dunn procedure of the Kruskal-Wallis test (30) . Differences in C3 deposition and in levels of opsonic killing of heterologous strains were identified by analysis of variance (ANOVA); the Scheffe F test was used to determine the significance levels of these differences. Most of the calculations described above were performed on a Macintosh II computer with the StatView SE+graphics software program (Abacus Concepts, Inc., Berkeley, Calif.).
RESULTS
Properties of MEP vaccines. The chemical composition, molecular size, and immunogenicity in mice of human MEP vaccine lot 1 have been reported previously (9) ; this preparation was referred to as lot 1 in the previous report. Briefly, lot 1 vaccine was a polymer with a Kav of 0.26, and it was composed of >99.9% uronic acid, with a 4:1 ratio of mannuronic acid to guluronic acid residues. It elicited opsonic antibodies in mice at doses of 1 and 10 ,ug per mouse, but it elicited only nonopsonic antibodies at doses of .20 ,ug per mouse. Human MEP vaccine lot 2 was similar-with only slight differences-to a nonhuman version (referred to as lot 2) also described previously (9) . Human MEP vaccine lot 2 was composed of 82% mannuronic acid and 18% guluronic acid, it had a Kav of 0.102 on a column (1.6 by 100 cm) of Sepharose CL4B, and it contained <1% protein or nucleic acid. Both human vaccine lots contained 4.0% acetate by weight. Human MEP vaccine lot 2 had an immunogenicity profile in mice similar to that previously reported for nonhuman lot 2 (9), as measured by increases in antibody titers (detected by ELISA) and in opsonic titers (detected by a phagocytosis assay). Thus, human lot 2 induced a :fourfold rise in ELISA titers and opsonic titers at doses of 1 to 50 ,ug per mouse. Human MEP vaccine lots 1 and 2 both passed all U.S. Food and Drug Administration-mandated evaluations for pyrogenicity, endotoxin content, and general safety in mice and guinea pigs.
Response to vaccination with human MEP vaccine lot 1. Twenty-eight individuals (16 men and 12 women) were vaccinated subcutaneously at least once with MEP human vaccine lot 1 in doses of 10 to 150 ,ug. Booster doses of 100 ug were given to eight individuals 2 to 6 weeks after their initial immunization; in addition, three individuals given initial doses of 100 ,ug received booster doses of 150 ,ug 4 weeks later. The booster doses had no effect on antibody responses and elicited reactions comparable to those to the initial doses. The vaccine was well tolerated, and the adverse reactions documented were typical of those seen with other bacterial polysaccharide vaccines (3, 10, 17) . These reactions included erythema at the site of injection (diameters of 1 to 3 cm noted at 24 h) in the case 1 of 5 vaccinates given 10 ,ug, 2 of 5 vaccinates given 50 jig, 6 of 11 vaccinates given 100 jig, and 5 of 7 vaccinates given 150 jig. A total of 20 of the 28 vaccinates experienced mild tenderness at the injection site up to 48 h after immunization, but this reaction appeared to be independent of the dose. No additional toxicity was associated with booster doses. One individual had systemic symptoms-fever and headache-that commenced 48 h after immunization, but these symptoms were judged to be likely due to a viral syndrome rather than the vaccine.
The development of opsonic antibodies to mucoid P. aeruginosa after vaccination is shown in Response to immunization with 100 pg of human MEP vaccine lot 2. Studies with naive mice (9) indicated that human MEP vaccine lot 1 elicited opsonic antibodies at doses of 1 to 10 jig per mouse but that it elicited only nonopsonic antibodies at doses of 50 jig per mouse. In animals previously immunized with 50 ,ug of MEP, a booster dose of 1 to 10 ,ug of human lot 1 vaccine failed to elicit opsonic antibodies (9) . Thus, the results with these mice are like those with human vaccinates: in the presence of preexisting nonopsonic antibodies (either induced in mice or occurring naturally in humans), human vaccine lot 1 only poorly elicits opsonic antibodies. However, a vaccine composed of only the polymers of MEP with the largest molecular sizes elicited opsonic antibodies in mice with preexisting nonopsonic antibodies (9) . We thus prepared human MEP vaccine lot 2 and administered it initially to 20 individuals in a single 100-jig dose and later to 50 individualsfive groups of 10 given doses of 1, 10, 50, 100, and 300 jig, respectively-to determine whether this preparation elicited a better immune response than lot 1.
Among the 20 individuals given the initial 100-jig dose, there were 10 men and 10 women; five volunteers of each sex received the vaccine subcutaneously, and five of each sex received it intramuscularly. The subjects ranged in age from 20 through 49 years, and apart from moderate allergies in some instances, they were all in good health, with all vital signs and almost all complete blood count values within normal ranges. The rates of reaction did not differ with the route of administration. Since all reported reactions were characterized as mild, results for local reactions were pooled for all 20 vaccinates. At 20 min after vaccination, seven subjects (35%) had redness at the injection site, one (5%) had induration, two (10%) had pain, six (30%) had local tenderness, two (10%) (20) that this measurement coincides with increases in opsonic antibody levels. The increase in C3 deposition for the nonresponders was not significant, and that for the entire group was of borderline significance (P = 0.058, paired t test, two-sided).
The specificity of antibodies was evaluated by means of inhibition assays wherein serum samples were incubated with either purified MEP (100 ,ug/ml) or an irrelevant polysaccharide from P. aeruginosa before determination of the percentage of bacteria killed in the opsonophagocytosis assay. As shown in Fig. 3 , the sera exhibited significantly reduced killing activity (P < 0.001, paired t test, two-sided) if incubated with MEP before the opsonic assay but not if incubated with a serologically unrelated polysaccharide (P = 0.37, paired t test, two-sided).
The ability of the antibodies elicited in immune serum to kill heterologous strains of mucoid P. aeruginosa containing various ratios of mannuronic and guluronic acid monosaccharides in their MEP antigens is shown in Fig. 4 . The rates of killing for strains FRD 1 and 258 did not differ significantly from that for the vaccine strain 2192 (P > 0.05, ANOVA). The killing of mutant strain FRD 462, which contains no guluronic acid residues in its MEP, was slightly but significantly reduced (P = 0.05, ANOVA, Scheffe F test). Since all naturally occurring strains of mucoid P. aeruginosa analyzed to date contain some guluronic acid in their MEP antigens and since no strain with >50% guluronic acid residues has been described (31, 34) , the ability of antibodies elicited by vaccination with MEP from strain 2192 to kill mucoid P. aeruginosa strains expressing either low or high levels of guluronic acid indicates a potentially broad specificity of these opsonic antibodies for a large number of clinical isolates of mucoid P. aeruginosa.
Response 2. Fifty men were divided into five groups of 10 subjects each, and each group was given a single intramuscular injection of 1, 10, 50, 100, or 300 ,ug of vaccine. The vaccine was well tolerated, with all reported reactions judged to be mild. Of the 50 vaccinates, 15 had tenderness at the injection site, 2 had erythema, and 2 experienced a temperature rise to 37.3°C at some point during the first 48 h. Of the 15 vaccinates with tenderness, 11 received doses of 100 or 300 ,ug. All reactions subsided within 48 h. There were deviations from the normal ranges in <5% of the hematologic values among some subjects, with approximately the same number of measurements deviating from the normal ranges in the case of preimmunization blood samples as deviated from the normal ranges in the case of postimmunization blood samples. This indicated that out-of-range values for postimmunization blood samples were not due to vaccination but rather that they occurred at a rate comparable to that seen when this set of measurements is taken for blood samples from 50 humans. There was neither a pattern or consistent change in any particular hematologic value in the case of postimmunization samples, and none of the values outside the normal ranges were judged to be clinically significant (by HCM). Similar data accrued for serum chemistry studies and urinalyses of samples provided by these volunteers. One subject had an increase in atypical lymphocyte level from 0 to 20/mm3 after vaccination, but this change was thought to be due to a subacute viral infection.
The IgG antibody response to the vaccine measured by ELISA is shown in Fig. 5 as a single point determination for the serum samples obtained from all 50 individuals at 28 days after vaccination. All subjects had blood drawn 7, 14, 21, and 28 days after vaccination as well as on additional days up to 1 year. Most serum samples were tested by ELISAs utilizing dilutions between 1:100 and 1:25,600. The data shown in Fig. 5 are representative of the general response observed. Clearly, the responses were concentrated among recipients of 100 or 300 ,ug of MEP vaccine. Nine of 10 individuals given 100 ,ug and 4 of 10 given 300 ,ug showed increased IgG antibody binding to MEP at 28 days after vaccination. Responders maintained increased antibody levels for at least 1 year after vaccination. The ability to detect antibody by ELISA for the vaccinates immunized with human lot 2 vaccine (as opposed to those given human lot 1) was ascribed to use of the polymers with larger molecular sizes for sensitization of the ELISA plates. Use of smaller polymers (similar to human lot 1) for sensitization of ELISA plates did not result in detectable differences in antibody binding in the case of these or other serum samples.
The opsonic responses measured at 28 days after vaccination with human MEP vaccine lot 2 at doses of 1 to 300 jig are shown in Fig. 6 . Titers of opsonic antibody did not increase among vaccinates given 1 or 10 jig (data not shown); in contrast, three recipients of 50 jig, nine recipients of 100 jig, and four recipients of 300 jig responded to vaccination by producing opsonizing antibodies (P < 0.001, Kruskal-Wallis analysis). Titers in the group given 100 jig were significantly higher (P < 0.05, Dunn procedure of Kruskal-Wallis analysis) than those in the groups given 1, 10, or 50 jig. In general, the (24) and have also shown that sera from CF patients contain immune complexes capable of sensitizing concanavalin A-activated human peripheral-blood T cells, which can kill the murine hybridoma cells secreting MEP-specific opsonic antibodies (24) . In this experimental system, the polymers of MEP with larger molecular sizes are less efficient than smaller polymers in promoting T-cell-mediated killing of target hybridoma cells (unpublished observation). This observation suggests that the larger polymers may interact with membrane-bound antibody on B cells in a manner that renders these cells less susceptible to cytotoxic activity.
In both the study with human MEP vaccine lot 1 and the initial study of human MEP vaccine lot 2 (with 20 individuals given a single 100-,ug dose), men made up the majority of the responders. We do not know whether this is a general phenomenon, since these sample sizes are too small for any substantive conclusions. However, MEP vaccine will first be administered to volunteer plasma donors in order to produce a hyperimmune intravenous IgG preparation that can be used for evaluation of the therapeutic efficacy of these antibodies (given via passive infusion) in colonized CF patients. Since the vast majority of plasma donors are men, a preferential response of males to this vaccine would not be problematic in these initial clinical evaluations. However, if there are indications of potential protective efficacy of the vaccine against chronic infection with P. aeruginosa if administered to uncolonized CF patients, then it will be critical to assess genderassociated differences in responses.
In the first portion of the study with human lot 2 vaccine, four of five men immunized intramuscularly responded with opsonic antibodies, whereas only two of five men immunized subcutaneously responded. While these sample sizes are obviously too small for an evaluation of the significance of this observation, the fact that reactions to administration by the two routes were comparable led us to use the intramuscular route in dose-response studies. Human lot 1 vaccine was given only by the subcutaneous route; this point may have accounted, in part, for the poor immune response to this preparation. While we cannot completely exclude this explanation for the difference between the immune responses to lots 1 and 2, the difference in molecular size appears to be more critical; specifically, the responses of these volunteers strongly parallel those of mice (9) , in the case of which all vaccines were given by the same route. Moreover, opsonic antibody elicited by human lot 2 vaccine lasted for at least 24 months in all vaccinates available for study, while only two recipients of human lot 1 vaccine had long-term antibody responses.
MEP expressed by P. aeruginosa is composed of two constituent monosaccharides: aO-L-guluronic acid and ,-D-mannuronic acid, the latter sugar being partially acetylated. However, different mucoid strains produce MEP antigens with variable mannuronic acid-to-guluronic acid ratios (-10:1 to close to 1:1) (31, 34) , and so it was important to determine that antibodies elicited by one preparation were able to opsonize different mucoid P. aeruginosa strains expressing different MEP antigens. We found that the MEP from strain 2192, composed of about a 4:1 ratio of mannuronic acid to guluronic acid, elicited human antibodies that mediated opsonic killing of a clinical isolate whose MEP contained 55% mannuronic acid (1.2:1 mannuronic acid-to-guluronic acid ratio) and a clinical isolate whose MEP contained 90% mannuronic acid (9:1 mannuronic acid-to-guluronic acid ratio). In addition, the laboratory-derived mutant strain FRD 462 produces an MEP antigen composed solely of mannuronic acid. Although there was slightly less killing of strain FRD 462 by antibodies from seven vaccinates, as shown in Fig. 5 (P = 0.05), most of the vaccinates' sera efficiently mediated opsonic killing of this strain. This finding implies that the epitope recognized by some populations of MEP-specific opsonic antibodies is composed solely of mannuronic acid residues, the major constituent of most MEP antigens.
In conclusion, we have demonstrated that purified MEP from mucoid P. aeruginosa strain 2192 is safe and immunogenic in human adults when the polymers with the largest molecular sizes are used for the vaccine. The optimal dose appears to be 100 pug, and the immune response is maintained for up to 2 years. A third lot of MEP vaccine for human studies has been administered to plasma donors in order to prepare hyperimmune intravenous IgG material for eventual clinical evaluation with CF patients (27) . Previous work has indicated that almost all CF patients fail to respond to chronic infection with mucoid P. aeruginosa by producing opsonic antibodies to MEP, while some CF patients who survive into the second to fourth decades of life without chronic infection do have MEP-specific opsonic antibodies in serum (22) . If the progression of chronic P. aeruginosa lung infections in CF patients is due to the lack of MEP-specific opsonic antibodies, then provision of these antibodies by active or passive immunization should theoretically help to halt progression. The demonstration here of the properties of an MEP vaccine that are needed to elicit these antibodies in humans will allow further evaluation of this hypothesis.
